Last reviewed · How we verify
Glucophage tablets and Victoza
Glucophage (metformin) reduces hepatic glucose production and improves insulin sensitivity, while Victoza (liraglutide) stimulates insulin secretion and reduces glucagon in response to blood glucose levels.
Glucophage (metformin) reduces hepatic glucose production and improves insulin sensitivity, while Victoza (liraglutide) stimulates insulin secretion and reduces glucagon in response to blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glucophage tablets and Victoza |
|---|---|
| Also known as | Glucophage tablets and Victoza 6 mg/ml solution for injection in pre-filled pen |
| Sponsor | University Medical Centre Ljubljana |
| Drug class | Biguanide (metformin) and GLP-1 receptor agonist (liraglutide) |
| Target | AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake, primarily through AMPK activation. Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying. Together, they provide complementary glucose-lowering effects for type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, vomiting)
- Hypoglycemia
- Headache
- Lactic acidosis (metformin, rare)
Key clinical trials
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- HbA1c Variability in Type II Diabetes (NA)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes (PHASE1, PHASE2)
- RISE Adult Medication Study (PHASE3)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (PHASE3)
- A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucophage tablets and Victoza CI brief — competitive landscape report
- Glucophage tablets and Victoza updates RSS · CI watch RSS
- University Medical Centre Ljubljana portfolio CI